Stockopedia Stock Page For Brainjuicer

System 1 research

Edison Investment Research — Wed, 03 Apr 2013 07:24:24 +0100

Edison Investment Research published:
BrainJuicer is an industry disruptor with a differentiated offer in market research, basing its suite of tools around System 1 thinking #8211; the instinctive, intuitive and emotional reaction to stimulus, as opposed to self-reported rationalisation. FY12 results were affected by a downturn in client projects commissioned in the final weeks of the year that exposed the group#8217;s operational leverage but we anticipate growth will resume in FY13, allowing the historic valuation premium gradually to rebuild.

Better than feared

Edison Investment Research — Thu, 17 Jan 2013 13:46:58 +0000

Edison Investment Research published:
The year-end trading update indicates results ahead of those to which we moved after November#8217;s warning, with revenue marginally ahead of the previous year and better-than-expected cost containment. The revenue shortfall has been predominantly in the more traditional product offering, which provides some encouragement that the more novel #8216;Juicy#8217; products are continuing to build traction. We have left our FY13 forecasts as they stand for now, until we have a better feel for trading patterns into the new financial year. The shares are likely to mark time until the outlook...

Uncharted waters

Edison Investment Research — Wed, 21 Nov 2012 14:29:36 +0000

Edison Investment Research published:
Yesterday#8217;s trading update represents the first major setback in BrainJuicer#8217;s record, although it is not yet possible to determine the extent of its impact. Results are always heavily biased to the final weeks of the year, with material uncertainty over the outcome, but this is the first time earlier forecasts look unachievable. The encouraging element of the news is that BrainJuicer#8217;s innovative #8216;Juicy#8217; products continue to build strongly and newer territories, such as Brazil and China, are gaining ground.

Note on Brainjuicer by PhilH

PhilH — Sun, 18 Nov 2012 14:11:35 +0000

PhilH -:
Revenue weighted to 2nd half of each year

Consistently juicy

Edison Investment Research — Wed, 26 Sep 2012 08:44:17 +0100

Edison Investment Research published:
There were no surprises in BrainJuicer#8217;s interim numbers, just a continuation of strong performance well above the level of growth in the market. We are keeping our full-year forecasts unchanged. BrainJuicer continues to broaden its geographic base and punch well above its weight in terms of industry profile. The rating, towards the top of the international peer group, reflects the relatively tight shareholder base and the group#8217;s consistent delivery of premium growth.

Juice on track

Edison Investment Research — Thu, 19 Jul 2012 11:35:12 +0100

Edison Investment Research published:
BrainJuicer#8217;s pre-close trading update confirms that the group is on track to meet full-year expectations, with progress in the key US market continuing well. While the US is a huge market, it is also inherently conservative, so the group#8217;s culture of tackling market research using innovative techniques can take time to break through. The rating may be towards the top end of the international peer group, but the earnings growth reflects that BrainJuicer continues to punch well above its weight.

Searching for stock opportunities in sliding markets

Ben Hobson — Thu, 19 Apr 2012 12:24:53 +0100

Ben Hobson published:
Analysts are divided on whether market falls of recent weeks represent a mere blip or more significant correction for equities but no-one can argue that the past month has been unkind to stocks. For those of us with an eye on the blistering performance of momentum strategies during the early part of this year, the universe of stocks has got a hell of a lot smaller. Indeed, by shedding 300 points since mid-March, the FTSE 100 has been on a dire run of the like not seen since last June. But it’s...

Food for thought from Brainjuicer, Service Powers ahead and Stellar update from STEL

Hybridan — Tue, 27 Mar 2012 19:22:07 +0100

Hybridan published:
3d Diagnostic Imaging (LON:3DD) (LON: 3DD 0.6p/£1.45m) 3D Diagnostics, which owns the protected rights to a technology platform with a number of significant potential commercial products, announced interim results for the 6 months to 31 December 2011. Revenue suffered a significant drop to £67k (2010: £566k) whilst a slightly wider pretax loss of £987k (2010: £981k). Cash on the balance sheet has also fallen to £1.07m (2010: £2.02m). Whilst the results for the period were not positive, the Company stated that it now sees some early signs of an improvement...

MR reconfigured

Edison Investment Research — Tue, 27 Mar 2012 14:01:48 +0100

Edison Investment Research published:
BrainJuicer continues its enviable record of delivering strong growth in revenue and profits. Its culture of innovation, challenging the established market research (MR) wisdom, clearly differentiates the group from its peers, but also makes it harder to win clients in a conservative market place. That it does so is testament to the value that its internally-developed products deliver. The geographic expansion continues, funded from cash flow and with a cash positive balance sheet. The comparatively full rating reflects the record and looks much less demanding in an international context.

Hybridan Small Cap Wrap - Good facts from IPSO, Stellar update for STEL and food for thought from BrainJuicer

Hybridan — Wed, 25 Jan 2012 00:13:10 +0000

Hybridan published:
A reasonably positive week was had in the financial markets, with the FTSE closing some 100 points higher at 5,730 and the AIM All Share some 20 points higher at 755 points. An increase in UK unemployment to 8.4 per cent and worry around UK GDP did not explain this positive week, though retail sales in December were announced to have risen (2.6 per cent higher than in December 2010) as shops pushed through with heavy price cutting. UK debt surpassed £1 trillion for the first time this week and...